(R)-Lansoprazole-d4

• UNSPSC Description:

  (R)-Lansoprazole-d4 is deuterium labeled (R)-Lansoprazole. (R)-Lansoprazole is the R enantiomer of Lansoprazole, Lansoprazole (AG 1749) is an orally active proton pump inhibitor which prevents the stomach from producing acid. Lansoprazole (AG 1749) is a potent brain penetrant neutral sphingomyelinase (N-SMase) inhibitor (exosome inhibitor)[1][2].

• Target Antigen:

  Isotope-Labeled Compounds; Proton Pump

• Type:

  Isotope-Labeled Compounds

• Related Pathways:

  Membrane Transporter/Ion Channel;Others

• Applications:

  COVID-19-immunoregulation

• Field of Research:

  Inflammation/Immunology

• Purity:

  99.13

• Solubility:

  10 mM in DMSO

• Smiles:

  O=[S@@](C1=NC2=C([2H])C([2H])=C([2H])C([2H])=C2N1)CC3=NC=CC(OCC(F)(F)F)=C3C

• Molecular Weight:

  373.39

• References & Citations:

  [1]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-216.|[2]Huarui Zhang, et al. Advances in the discovery of exosome inhibitors in cancer. J Enzyme Inhib Med Chem. 2020 Dec;35(1):1322-1330.|[3]Kokufu, T., et al., Effects of lansoprazole on pharmacokinetics and metabolism of theophylline. Eur J Clin Pharmacol, 1995. 48(5): p. 391-5.|[4]M Miura, et al. Pharmacokinetic differences between the enantiomers of lansoprazole and its metabolite, 5-hydroxylansoprazole, in relation to CYP2C19 genotypes. Eur J Clin Pharmacol. 2004 Nov;60(9):623-8.

• Shipping Conditions:

  Blue Ice

• Storage Conditions:

  -20°C, 3 years (Powder)

• Clinical Information:

  No Development Reported